Skip navigation
logo
(AFX UK Focus) 2009-09-01 11:29
BRIEF-Biovail says Acadia's phase 3 trial of Parkinson's drug misses primary endpoint
Article layout: raw

Sept 1 (Reuters) - Biovail Corp:

  • ANNOUNCES RESULTS FROM ACADIA'S PHASE III TRIAL OF PIMAVANSERIN IN
    Parkinson's disease psychosis

  • SAYS PIMAVANSERIN MISSES PRIMARY ENDPOINT OF ANTIPSYCHOTIC EFFICACY

  • SAYS MEETS KEY SECONDARY ENDPOINT OF MOTORIC TOLERABILITY

    ((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here)

    COPYRIGHT

    Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

  • Re-organisations, re-structurings, name changes, AGM, EGM
    Article layout: raw
    Jump back to site navigation